Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedKC
Kalehua Capital
Activity from announced rounds
Activity in this selectiont-rowe-price-associates-5d4ec0e4
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $152M 1 disclosed · full round size, not this investor’s share